Status:
UNKNOWN
Evaluate the Effect and Safety of Pu Yang Wan Wu Tang and Western Medicine on Chronic Kidney Disease
Lead Sponsor:
Taipei Medical University Hospital
Conditions:
Chronic Kidney Diseases
Eligibility:
All Genders
20-80 years
Phase:
PHASE2
PHASE3
Brief Summary
The indication of Pu Yang Wan Wu Tang is stroke sequelae, such as half body paralysis, aphasia and muscle weakness. Pu Yang Wan Wu Tang is proved to have the effect of protecting nerve and blood vess...
Eligibility Criteria
Inclusion
- Participants' age is between 20 to 80 years.
- Participants CKD stage are from 2 to 4(eGFR from 89 to 15)
- Participants under regular western medicine therapy.
- Participants who agree to follow the trial protocol.
- Participants who can complete the study treatment and assessments.
Exclusion
- Participants who are already under hemodialysis, Peritoneal Dialysis or kidney transplant.
- Participants who are participating in other clinical trials.
- Participants with hematopoietic system diseases, severe psychiatric or psychological disorder, or cancer.
- Women who are pregnant.
Key Trial Info
Start Date :
May 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 20 2023
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT05387187
Start Date
May 1 2022
End Date
June 20 2023
Last Update
June 26 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Taipei Medical University
Taipei, Taiwan, 110